scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.38) by 2.63 percent. This is a 54.17 percent decrease over losses of $(0.24) per share from the same period last year.
What’s The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New Paper
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), announced the publication of a paper entitled, “Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment,” in the Journal of Neurodevelopmental Disorders.
